Diacon et al.2009 [24]
|
RCT
|
June.2007-January.2008
|
A hospital, South Africa
|
adults, MDR-TB, treatment-naive, pulmonary sputum smear-positive;
Excl. HIV-positive on ART or CD4 < 300 cells/µL.
|
44
|
Arm1:BR + Bdq
Arm2:BR + placebo
|
8 weeks
|
Diacon et al.2012a [25]
|
RCT
|
N.S
|
A hospital, South Africa
|
adults, MDR-TB; pulmonary sputum smear-positive;
Excl. HIV-positive on ART or CD4 < 300 cells/µL.
|
44
|
Arm1:BR + Bdq
Arm2:BR + placebo
|
104 weeks
|
Diacon et al.2012b [26]
|
RCT
|
October,2010-August,2011
|
A hospital, South Africa
|
Adults, treatment-naive, pulmonary Rs-TB;
Excl. HIV-positive on ART or CD4 ≤ 300 cells/µL.
|
85
|
Arm 1: Pa-Bdq
Arm 2: Bdq
Arm 3: Bdq-Z
|
Arm 4: Pa-Z
|
Arm 5: Pa-Mfx-Z
|
Arm 6: HRZE
|
|
2 weeks
|
Diacon et al.2014 [27]
|
RCT
|
June.2007-March.2010
|
Brazil, India, Latvia, Peru, the Philippines, Russia, South Africa, Thailand
|
adults, MDR-TB, treatment-naive, pulmonary sputum smear-positive;
Excl. HIV-positive on CD4 < 300 cells/µL.
|
160
|
Arm1:BR + Bdq
Arm2:BR + placebo
|
120 weeks
|
Diacon et al.2015 [28]
|
RCT
|
October 2012-April 2013
|
outpatient clinics in Cape Town, South Africa
|
adults, treatment-naive, pulmonary sputum smear-positive Rs and Hs-TB;
Excl. HIV-positive with CD4 ≤ 300 cells/µL
|
105
|
Arm1: Bdq -Pa-Z-C
Arm2: Bdq -Pa-Z
Arm3: Bdq -Pa-C
Arm4: Bdq -Z-C
Arm5: Z
Arm6:C
Arm7: HRZE
|
2 weeks
|
Esmail et al.2022 [29]
|
RCT
|
November, 2015- December, 2020
|
Five centers, South Africa
|
adults, treatment-naive, MDR/RR-TB, pulmonary sputum smear-positive;
Excl. XDR-TB, pre-XDR-TB;
|
111
|
Arm1: BR + Bdq
Arm2: BR
|
96 weeks
|
Ling et al.2021 [30]
|
RCT
|
Septermber,2018-January ,2020;
|
A hospital, China
|
adults, MDR-TB;
Excl. HIV-positive;
|
64
|
Arm1:BR + Bdq
Arm2:BR
|
24 weeks
|
Mou.2021 [31]
|
RCT
|
February 2019-May,2020
|
A hospital, China
|
adults, MDR-TB
|
63
|
Arm1:BR + Bdq
Arm2:BR + placebo
|
72 weeks
|
Ren et al.2021 [32]
|
RCT
|
December,2017-June,2019;
|
A hospital, China
|
adults, MDR-TB;
Excl. HIV- positive, HBV-positive
|
60
|
Arm1:BR + Bdq
Arm2:BR
|
24 weeks
|
Tweed et al.2019 [33]
|
RCT with single Rr-TB arm
|
October, 2014 - February, 2016;
|
South Africa, Tanzania, Uganda
|
Adults, RR-TB f ; treatment-naive pulmonary, sputum smear-positive Rs-TB;
Excl. HIV-positive with CD4 < 200 cells/mL;
|
240
|
Arm 1: Bdq-Pa-Z
Arm 2: Bdq200- Pa-Z
Control: HRZE
|
8 weeks
|
Wang 2019[34]
|
RCT
|
March,2019-August.2020;
|
A hospital, China
|
adults, MDR-TB;
|
69
|
Arm1:BR + Bdq
Arm2:BR
|
26 weeks
|
Wu 2020 [35]
|
RCT
|
January ,2018-July,2018;
|
A hospital, China
|
adults, MDR-TB; sputum smear-positive;
|
34
|
Arm1:BR + Bdq
Arm2:BR
|
24 weeks
|
Fu et al.2021 [36]
|
PCS
|
April,2019-August,2020
|
A hospital, China
|
DR/MDR-TB
Excl. HIV-positive, AIDS;
|
103
|
Arm1:BR + Bdq
Arm2:BR
|
16 weeks
|
Chang et al.2021 [37]
|
PCS
|
January ,2018-June,2019
|
A hospital, China
|
Adults, MDR-TB
|
90
|
Arm1:BR + Bdq
Arm2:BR
|
24 weeks
|
Kempker et al.2020 [38]
|
PCS
|
December,2015-May,2017
|
A center, Georgia, USA
|
Adults, Smear positive MDR-TB
|
95
|
Arm 1: BR + Bdq
Arm 2: BR + DLM
|
24 weeks
|
Kim et al.2018 [39]
|
PCS
|
January,2015-October,2017
|
Hospitals, South Korea
|
Adults, MDR-TB
|
50
|
Arm 1: BR + Bdq
Arm 2: BR + DLM
|
24 weeks
|
Olayanju et al.2018 [40]
|
PCS
|
January,2008-June,2017
|
A hospital, South Africa
|
Adults, XDR-TB
|
272
|
Arm1:BR + Bdq
Arm2:BR
|
96 weeks
|
Chen et al.2021[41]
|
RCS
|
June, 2016- August, 2019
|
A center, China
|
Adults, RR/MDR-TB
|
112
|
Arm1:BR + Bdq
Arm2:BR
|
24 weeks
|
Chesov et al.2021 [42]
|
RCS
|
2016–2018
|
the Republic of Moldova
|
Adults, sputum smear-positive MDR-TB
|
228
|
Arm1:BR + Bdq
Arm2:BR
|
24 weeks
|
Bastard et al.2018 [43]
|
RCS
|
September,2005-April,2015;
|
Armenia
|
Adults, MDR-TB
|
140
|
Arm1: BR + Bdq
Arm2: BR
|
24 weeks
|
Kang et al.2020 [44]
|
RCS
|
September,2016-February,2018;
|
A center, South Korea
|
MDR-TB
|
215
|
Arm 1: BR + Bdq
Arm 2: BR + DLM
|
d48 weeks
|
Liu et al.2021[45]
|
RCS
|
January ,2017- January ,2018
|
A hospital, China
|
Adults, RR/MDR-TB
|
174
|
Arm1:BR + Bdq
Arm2:BR
|
96 weeks
|
Padayatchi et al.2020 [46]
|
RCS
|
January,2014-November,2015
|
A hospital, South Africa
|
Adults, DR-TB
|
256
|
Arm1:BR + Bdq
Arm2:BR
|
24 weeks
|
Ren et al.2021[47]
|
RCS
|
June,2018-January,2020
|
A hospital, China
|
Adults, MDR-TB
|
60
|
Arm1:BR + Bdq
Arm2:BR
|
24 weeks
|
Schnippel et al.2018 [48]
|
RCS
|
July,2014-March,2016;
|
EDRweb, South Africa
|
Adults, DR-TB
|
19617
|
Arm1:BR + Bdq
Arm2:BR + SLID
|
72 weeks
|
Taune et al.2019 [49]
|
RCS
|
June, 2015-Decemeber,
2017;
|
Papua New Guinea
|
Adults, RR/MDR-TB
|
277
|
Arm1:BR + Bdq
Arm2:BR
|
24 weeks
|
Zhang et al.2022 [50]
|
RCS
|
Novvmber,2018-December,2020
|
A center, China
|
Adults, RR/MDR-TB
|
127
|
Arm1:BR + Bdq
Arm2:BR
|
24 weeks
|
Zhao et al.2019 [51]
|
RCS
|
October,2014-October,2016;
|
EDRweb, South Africa
|
Adults, MDR-TB
Excl. pre-XDR-TB,XDR-TB
|
330
|
Arm1:BR + Bdq
Arm2:BR
|
48 weeks
|
Hwang et al.2021 [52]
|
RCS
|
September,2016-February,2018;
|
A hospital, South Africa
|
Adults, MDR-TB
|
260
|
Arm 1: BR + Bdq
Arm 2: BR + DLM
|
24 weeks
|
ART, anti-retroviral treatment; CD4, CD4 T-lymphocytes count; TB, tuberculosis; Hs-TB, isoniazid-susceptible tuberculosis; Rs, rifampicin-susceptible; Rr-TB, rifampicin-resistant tuberculosis; DR-TB: drug-resistant tuberculosis; MDR-TB, multidrug-resistant tuberculosis; pre-XDr-TB, pre-extensively resistant tuberculosis; EDRweb, web-based electronic drug-resistant tuberculosis register; BR: Background regimen; |
BDQ, bedaquiline; LZD, linezolid; Mfx, moxifloxacin; Pa, pretomanid; SOC, standard-of-care; SLID: second-line injectable drug; DLM: delamanid; HRZE: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol; Z, pyrazinamide; |
RCT, randomized controlled trial; NRC, nonrandomized controlled trial; RCS, retrospective cohort study; PCS,prospective cohort study; Z, pyrazinamide; pre-XDr-TB, pre-extensively resistant tuberculosis. EDRweb, web-based electronic drug-resistant tuberculosis register. |